Cambridge, United Kingdom – 1 March 2021 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the appointment of Kamraan Shariff as Chief Business Development Officer effective immediately. Kamraan will be responsible for developing and implementing the Company’s global business development strategy that will be instrumental in accelerating Congenica’s growth.
Kamraan Shariff has more than 25 years of experience in corporate development, venture capital, mergers & acquisitions and investment banking across the US, Europe and Asia. Prior to joining Congenica, Kamraan was Head of Corporate Development at Drawbridge Health, a blood sampling medtech business, where he was responsible for global strategic partnerships. Previously, he was a Managing Director at GE Ventures in addition to holding senior positions within the M&A division of both GE & GE Capital across Europe and Asia. Kamraan started his career in Investment Banking, working at ANZ Investment Bank for almost 12 years before moving into business development roles.
Kamraan has a master’s degree in International Banking & Financial Services from the University of Reading and a bachelor’s degree in Economics from the University of Leeds.
David Atkins, Chief Executive Officer at Congenica, said: “Kamraan has an impressive track record of international deal execution, which will be hugely valuable to Congenica as we deliver on our strategy of global expansion through key partnerships. It is a pleasure to welcome someone with Kamraan’s strategic capabilities to this newly formed role and the senior leadership team.”
On his appointment, Kamraan Shariff, said: “Congenica’s technology has the potential to improve patients’ lives worldwide by providing life- changing answers. It is exciting to join such an innovative and fast growing business where I look forward to working with the rest of the team to make a real impact in rare diseases and oncology.”
Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers to provide life-changing answers that will in future improve wellbeing and disease management.
Congenica’s world-leading software enables rapid genomic data analysis at scale, performing 20x faster than industry averages and providing a 30% higher analytical yield, reducing genomic interpretation costs by up to 95%.
Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.